Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.

Bahjat M, de Wilde G, van Dam T, Maas C, Bloedjes T, Bende RJ, van Noesel CJM, Luijks DM, Eldering E, Kersten MJ, Guikema JEJ.

Cell Cycle. 2019 Sep;18(18):2307-2322. doi: 10.1080/15384101.2019.1646068. Epub 2019 Jul 26.

2.

De novo gene mutations in normal human memory B cells.

Slot LM, Wormhoudt TAM, Kwakkenbos MJ, Wagner K, Ballering A, Jongejan A, van Kampen ACM, Guikema JEJ, Bende RJ, van Noesel CJM.

Leukemia. 2019 May;33(5):1219-1230. doi: 10.1038/s41375-018-0289-4. Epub 2018 Oct 23.

PMID:
30353030
3.

The Complex Interplay between DNA Injury and Repair in Enzymatically Induced Mutagenesis and DNA Damage in B Lymphocytes.

Bahjat M, Guikema JEJ.

Int J Mol Sci. 2017 Aug 30;18(9). pii: E1876. doi: 10.3390/ijms18091876. Review.

4.

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.

Guikema JE, Amiot M, Eldering E.

Expert Opin Ther Targets. 2017 Aug;21(8):767-779. doi: 10.1080/14728222.2017.1349754. Epub 2017 Jul 18. Review.

PMID:
28670929
5.

Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay.

Bahjat M, Bloedjes TA, van der Veen A, de Wilde G, Maas C, Guikema JEJ.

J Vis Exp. 2017 Jun 9;(124). doi: 10.3791/55703.

6.

ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.

Dzikiewicz-Krawczyk A, Kok K, Slezak-Prochazka I, Robertus JL, Bruining J, Tayari MM, Rutgers B, de Jong D, Koerts J, Seitz A, Li J, Tillema B, Guikema JE, Nolte IM, Diepstra A, Visser L, Kluiver J, van den Berg A.

Leukemia. 2017 Jun;31(6):1470-1473. doi: 10.1038/leu.2017.94. Epub 2017 Mar 23. No abstract available.

PMID:
28331227
7.

Computational Model Reveals Limited Correlation between Germinal Center B-Cell Subclone Abundancy and Affinity: Implications for Repertoire Sequencing.

Reshetova P, van Schaik BD, Klarenbeek PL, Doorenspleet ME, Esveldt RE, Tak PP, Guikema JE, de Vries N, van Kampen AH.

Front Immunol. 2017 Mar 6;8:221. doi: 10.3389/fimmu.2017.00221. eCollection 2017.

8.

Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.

van Andel H, Ren Z, Koopmans I, Joosten SP, Kocemba KA, de Lau W, Kersten MJ, de Bruin AM, Guikema JE, Clevers H, Spaargaren M, Pals ST.

Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):376-381. doi: 10.1073/pnas.1618650114. Epub 2016 Dec 27.

9.

B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.

Slot LM, Hoogeboom R, Smit LA, Wormhoudt TA, Biemond BJ, Oud ME, Schilder-Tol EJ, Mulder AB, Jongejan A, van Kampen AH, Kluin PM, Guikema JE, Bende RJ, van Noesel CJ.

Am J Pathol. 2016 Dec;186(12):3273-3284. doi: 10.1016/j.ajpath.2016.07.027. Epub 2016 Oct 15.

PMID:
27750045
10.

The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling.

Ochodnicka-Mackovicova K, Bahjat M, Maas C, van der Veen A, Bloedjes TA, de Bruin AM, van Andel H, Schrader CE, Hendriks RW, Verhoeyen E, Bende RJ, van Noesel CJ, Guikema JE.

J Immunol. 2016 Oct 1;197(7):2918-29. doi: 10.4049/jimmunol.1501989. Epub 2016 Aug 24.

11.

Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA.

Slinger E, Wensveen FM, Guikema JE, Kater AP, Eldering E.

Haematologica. 2016 Sep;101(9):e374-7. doi: 10.3324/haematol.2016.142323. Epub 2016 Jun 13. No abstract available.

12.

Identification of a novel stereotypic IGHV4-59/IGHJ5-encoded B-cell receptor subset expressed by various B-cell lymphomas with high affinity rheumatoid factor activity.

Bende RJ, Janssen J, Wormhoudt TA, Wagner K, Guikema JE, van Noesel CJ.

Haematologica. 2016 May;101(5):e200-3. doi: 10.3324/haematol.2015.139626. Epub 2016 Feb 8. No abstract available.

13.

NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.

Ochodnicka-Mackovicova K, Bahjat M, Bloedjes TA, Maas C, de Bruin AM, Bende RJ, van Noesel CJ, Guikema JE.

Blood. 2015 Sep 10;126(11):1324-35. doi: 10.1182/blood-2015-01-621623. Epub 2015 Jul 7.

14.

MYC in diffuse large B-cell lymphoma: always the bad guy?

Kersten MJ, Guikema JE.

Leuk Lymphoma. 2015;56(11):3003-4. doi: 10.3109/10428194.2015.1048445. Epub 2015 Jun 18. No abstract available.

PMID:
25944471
15.

Stereotypic rheumatoid factors that are frequently expressed in mucosa-associated lymphoid tissue-type lymphomas are rare in the labial salivary glands of patients with Sjögren's syndrome.

Bende RJ, Slot LM, Hoogeboom R, Wormhoudt TA, Adeoye AO, Guikema JE, van Noesel CJ.

Arthritis Rheumatol. 2015 Apr;67(4):1074-83. doi: 10.1002/art.39002.

16.

In vitro induction of antibody secretion of primary B-cell chronic lymphocytic leukaemia cells.

Hoogeboom R, Reinten RJ, Schot JJ, Guikema JE, Bende RJ, van Noesel CJ.

Leukemia. 2015 Jan;29(1):244-7. doi: 10.1038/leu.2014.266. Epub 2014 Sep 10. No abstract available.

PMID:
25204568
17.

Apurinic/apyrimidinic endonuclease 2 regulates the expansion of germinal centers by protecting against activation-induced cytidine deaminase-independent DNA damage in B cells.

Guikema JE, Linehan EK, Esa N, Tsuchimoto D, Nakabeppu Y, Woodland RT, Schrader CE.

J Immunol. 2014 Jul 15;193(2):931-9. doi: 10.4049/jimmunol.1400002. Epub 2014 Jun 16.

18.

ATM increases activation-induced cytidine deaminase activity at downstream S regions during class-switch recombination.

Khair L, Guikema JE, Linehan EK, Ucher AJ, Leus NG, Ogilvie C, Lou Z, Schrader CE, Stavnezer J.

J Immunol. 2014 May 15;192(10):4887-96. doi: 10.4049/jimmunol.1303481. Epub 2014 Apr 11.

19.

Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.

Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP.

Blood. 2013 Dec 5;122(24):3960-3. doi: 10.1182/blood-2013-04-497693. Epub 2013 Oct 7.

20.

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi.

Hoogeboom R, van Kessel KP, Hochstenbach F, Wormhoudt TA, Reinten RJ, Wagner K, Kater AP, Guikema JE, Bende RJ, van Noesel CJ.

J Exp Med. 2013 Jan 14;210(1):59-70. doi: 10.1084/jem.20121801. Epub 2013 Jan 7.

21.

A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient.

Hoogeboom R, Wormhoudt TA, Schipperus MR, Langerak AW, Dunn-Walters DK, Guikema JE, Bende RJ, van Noesel CJ.

Leukemia. 2013 Mar;27(3):738-40. doi: 10.1038/leu.2012.238. Epub 2012 Aug 20. No abstract available.

PMID:
22902363
22.

Activation-induced cytidine deaminase induces reproducible DNA breaks at many non-Ig Loci in activated B cells.

Staszewski O, Baker RE, Ucher AJ, Martier R, Stavnezer J, Guikema JE.

Mol Cell. 2011 Jan 21;41(2):232-42. doi: 10.1016/j.molcel.2011.01.007.

23.

Apurinic/apyrimidinic endonuclease 2 is necessary for normal B cell development and recovery of lymphoid progenitors after chemotherapeutic challenge.

Guikema JE, Gerstein RM, Linehan EK, Cloherty EK, Evan-Browning E, Tsuchimoto D, Nakabeppu Y, Schrader CE.

J Immunol. 2011 Feb 15;186(4):1943-50. doi: 10.4049/jimmunol.1002422. Epub 2011 Jan 12.

24.

A novel regulatory circuit in base excision repair involving AP endonuclease 1, Creb1 and DNA polymerase beta.

Pei DS, Yang XJ, Liu W, Guikema JE, Schrader CE, Strauss PR.

Nucleic Acids Res. 2011 Apr;39(8):3156-65. doi: 10.1093/nar/gkq1142. Epub 2010 Dec 20.

25.

p53 represses class switch recombination to IgG2a through its antioxidant function.

Guikema JE, Schrader CE, Brodsky MH, Linehan EK, Richards A, El Falaky N, Li DH, Sluss HK, Szomolanyi-Tsuda E, Stavnezer J.

J Immunol. 2010 Jun 1;184(11):6177-87. doi: 10.4049/jimmunol.0904085. Epub 2010 May 5. Erratum in: J Immunol. 2011 Nov 1;187(9):4920.

26.

The role of Apex2 in class-switch recombination of immunoglobulin genes.

Guikema JE, Stavnezer J, Schrader CE.

Int Immunol. 2010 Mar;22(3):213; author reply 213-4. doi: 10.1093/intimm/dxq003. No abstract available.

PMID:
20185435
27.

Reassessment of the role of Mut S homolog 5 in Ig class switch recombination shows lack of involvement in cis- and trans-switching.

Guikema JE, Schrader CE, Leus NG, Ucher A, Linehan EK, Werling U, Edelmann W, Stavnezer J.

J Immunol. 2008 Dec 15;181(12):8450-9.

28.

The roles of APE1, APE2, DNA polymerase beta and mismatch repair in creating S region DNA breaks during antibody class switch.

Schrader CE, Guikema JE, Wu X, Stavnezer J.

Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):645-52. doi: 10.1098/rstb.2008.0200. Review.

29.

Structure and consequences of IGH switch breakpoints in Burkitt lymphoma.

Guikema JE, Schuuring E, Kluin PM.

J Natl Cancer Inst Monogr. 2008;(39):32-6. doi: 10.1093/jncimonographs/lgn020.

PMID:
18647999
30.

Mechanism and regulation of class switch recombination.

Stavnezer J, Guikema JE, Schrader CE.

Annu Rev Immunol. 2008;26:261-92. doi: 10.1146/annurev.immunol.26.021607.090248. Review.

31.

APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination.

Guikema JE, Linehan EK, Tsuchimoto D, Nakabeppu Y, Strauss PR, Stavnezer J, Schrader CE.

J Exp Med. 2007 Nov 26;204(12):3017-26. Epub 2007 Nov 19. Erratum in: J Exp Med. 2007 Dec 24;204(13):3295.

32.

Activation-induced cytidine deaminase-dependent DNA breaks in class switch recombination occur during G1 phase of the cell cycle and depend upon mismatch repair.

Schrader CE, Guikema JE, Linehan EK, Selsing E, Stavnezer J.

J Immunol. 2007 Nov 1;179(9):6064-71. Erratum in: J Immunol. 2008 Jan 1;180(1):664.

33.

IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination.

Guikema JE, de Boer C, Haralambieva E, Smit LA, van Noesel CJ, Schuuring E, Kluin PM.

Genes Chromosomes Cancer. 2006 Sep;45(9):808-19.

PMID:
16736499
34.

H2AX is not affected in mantle cell lymphoma with 11q23 deletion.

Guikema JE, de Boer-Bergsma RW, Akkermans K, Schuuring E, Kluin PM.

Genes Chromosomes Cancer. 2006 Apr;45(4):426-7. No abstract available.

PMID:
16382446
35.

Quantitative RT-PCR analysis of activation-induced cytidine deaminase expression in tissue samples from mantle cell lymphoma and B-cell chronic lymphocytic leukemia patients.

Guikema JE, Rosati S, Akkermans K, Bende RJ, van Noesel CJ, van Krieken JH, Hansmann ML, Schuuring E, Kluin PM.

Blood. 2005 Apr 1;105(7):2997-8; discussion 2998-9. No abstract available.

PMID:
15781912
36.

Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination.

Guikema JE, Fenton JA, de Boer C, Kleiverda K, Brink AA, Raap AK, Estrov Z, Schuuring E, Kluin PM.

Genes Chromosomes Cancer. 2005 Feb;42(2):164-9.

PMID:
15543623
37.

Heterogeneity in the multiple myeloma tumor clone.

Guikema JE, Hovenga S, Vellenga E, Bos NA.

Leuk Lymphoma. 2004 May;45(5):857-71. Review.

PMID:
15291343
38.

CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases.

Guikema JE, Vellenga E, Abdulahad WH, Hovenga S, Bos NA.

Br J Haematol. 2004 Feb;124(3):299-308.

PMID:
14717776
39.

Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype.

Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ.

Cancer Res. 2003 Jul 15;63(14):3894-8.

40.

CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease.

Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R, Smit JW, Zhan F, Shaughnessy J Jr, Bos NA.

Br J Haematol. 2003 Apr;121(1):36-43.

PMID:
12670329
41.

Myeloma clonotypic B cells are hampered in their ability to undergo B-cell differentiation in vitro.

Guikema JE, Vellenga E, Bakkus MH, Bos NA.

Br J Haematol. 2002 Oct;119(1):54-61.

PMID:
12358903
42.

Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma.

de Bont ES, Guikema JE, Scherpen F, Meeuwsen T, Kamps WA, Vellenga E, Bos NA.

Cancer Res. 2001 Oct 15;61(20):7654-9.

43.

Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.

Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, Bos NA, Vellenga E.

Bone Marrow Transplant. 2000 Apr;25(7):723-8.

44.

Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation.

Guikema JE, Vellenga E, Veeneman JM, Hovenga S, Bakkus MH, Klip H, Bos NA.

Br J Haematol. 1999 Mar;104(4):748-54.

PMID:
10192436

Supplemental Content

Loading ...
Support Center